YM-207

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameYM-207

Drug Alias NameY1-antibody

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists

TargetsIntegrin alpha-IIb/beta-3

Therapy Area/IndicationsThromboembolismMyocardial Infarction

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesYamanouchi

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesYamanouchi

Active IndicationsN/A

Inactive IndicationsThromboembolismMyocardial Infarction

ATC CodeN/A